

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

ARIAD

RRID:SCR_008559

Type: Tool

Proper Citation

ARIAD (RRID:SCR_008559)

Resource Information

URL: <http://www.ariad.com/>

Proper Citation: ARIAD (RRID:SCR_008559)

Description: Cambridge, Massachusetts-based biotechnology company focused on cancer. Focus areas are blood cancers and solid tumors. Compounds: ponatinib, AP26113, ridaforolimus and AP1903., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Abbreviations: ARIAD

Synonyms: ARIAD Pharmaceuticals

Resource Type: material service resource, production service resource, reagent manufacture, service resource

Keywords: oncology, drug, therapy, treatment, drug development

Related Condition: Cancer

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: ARIAD

Resource ID: SCR_008559

Alternate IDs: nif-0000-31436

Old URLs: http://www.ariad.com/wt/page/regulation_kits

Record Creation Time: 20220129T080248+0000

Record Last Update: 20260905T132624+0000

Ratings and Alerts

No rating or validation information has been found for ARIAD.

No alerts have been found for ARIAD.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 55 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Netolicky J, et al. (2025) Distinct Regulation of Early Trafficking of the NMDA Receptors by the Ligand-Binding Domains of the GluN1 and GluN2A Subunits. The Journal of neuroscience : the official journal of the Society for Neuroscience, 45(26).

Moretto E, et al. (2023) The tetraspanin TSPAN5 regulates AMPAR exocytosis by interacting with the AP4 complex. eLife, 12.

Bonnet C, et al. (2023) Regulation of different phases of AMPA receptor intracellular transport by 4.1N and SAP97. eLife, 12.

Pathak S, et al. (2023) Inducible caspase 9-mediated suicide gene therapy using AAV6 vectors in a murine model of breast cancer. Molecular therapy. Methods & clinical development, 31, 101166.

Poulos A, et al. (2022) Single-motor and multi-motor motility properties of kinesin-6 family members. Biology open, 11(10).

Budaitis BG, et al. (2021) Pathogenic mutations in the kinesin-3 motor KIF1A diminish force generation and movement through allosteric mechanisms. The Journal of cell biology, 220(4).

Koyama-Honda I, et al. (2020) High-speed single-molecule imaging reveals signal transduction by induced transbilayer raft phases. The Journal of cell biology, 219(12).

Tsuchiya K, et al. (2019) Caspase-1 initiates apoptosis in the absence of gasdermin D. Nature communications, 10(1), 2091.

Tugnait M, et al. (2019) The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Clinical pharmacology in drug development, 8(6), 734.

Tapia D, et al. (2019) KDEL receptor regulates secretion by lysosome relocation- and autophagy-dependent modulation of lipid-droplet turnover. Nature communications, 10(1), 735.

Budaitis BG, et al. (2019) Neck linker docking is critical for Kinesin-1 force generation in cells but at a cost to motor speed and processivity. *eLife*, 8.

Stavrou EF, et al. (2019) Episomal vectors based on S/MAR and the β -globin Replicator, encoding a synthetic transcriptional activator, mediate efficient β -globin activation in haematopoietic cells. *Scientific reports*, 9(1), 19765.

Kwiatkowski BA, et al. (2019) DLGAP1 directs megakaryocytic growth and differentiation in an MPL dependent manner in hematopoietic cells. *Biomarker research*, 7, 13.

Paez-Mayorga J, et al. (2018) Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation. *Frontiers in cardiovascular medicine*, 5, 125.

Gozgit JM, et al. (2018) RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. *Oncotarget*, 9(51), 29654.

Hangen E, et al. (2018) Neuronal Activity and Intracellular Calcium Levels Regulate Intracellular Transport of Newly Synthesized AMPAR. *Cell reports*, 24(4), 1001.

Bedi S, et al. (2018) A comprehensive review on Brigatinib - A wonder drug for targeted cancer therapy in non-small cell lung cancer. *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society*, 26(6), 755.

Ono N, et al. (2017) Exposure to sequestered self-antigens in vivo is not sufficient for the induction of autoimmune diabetes. *PloS one*, 12(3), e0173176.

Ye YE, et al. (2017) Absorption, metabolism, and excretion of [^{14}C]ponatinib after a single oral dose in humans. *Cancer chemotherapy and pharmacology*, 79(3), 507.

Lonzari J, et al. (2016) Locked and proteolysis-based transcription activator-like effector (TALE) regulation. *Nucleic acids research*, 44(3), 1471.